These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 3829884)

  • 1. Steatosis and cirrhosis in an obese diabetic. Resolution of fatty liver by fasting.
    Keeffe EB; Adesman PW; Stenzel P; Palmer RM
    Dig Dis Sci; 1987 Apr; 32(4):441-5. PubMed ID: 3829884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrogenesis in fatty liver associated with obesity and diabetes mellitus type 2.
    Jaskiewicz K; Rzepko R; Sledzinski Z
    Dig Dis Sci; 2008 Mar; 53(3):785-8. PubMed ID: 17846888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ezetimibe improves hepatic steatosis in relation to autophagy in obese and diabetic rats.
    Chang E; Kim L; Park SE; Rhee EJ; Lee WY; Oh KW; Park SW; Park CY
    World J Gastroenterol; 2015 Jul; 21(25):7754-63. PubMed ID: 26167075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology.
    Loria P; Marchesini G; Nascimbeni F; Ballestri S; Maurantonio M; Carubbi F; Ratziu V; Lonardo A
    Atherosclerosis; 2014 Jan; 232(1):99-109. PubMed ID: 24401223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dietary modification dampens liver inflammation and fibrosis in obesity-related fatty liver disease.
    Larter CZ; Yeh MM; Haigh WG; Van Rooyen DM; Brooling J; Heydet D; Nolan CJ; Teoh NC; Farrell GC
    Obesity (Silver Spring); 2013 Jun; 21(6):1189-99. PubMed ID: 23666886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
    Belfort R; Harrison SA; Brown K; Darland C; Finch J; Hardies J; Balas B; Gastaldelli A; Tio F; Pulcini J; Berria R; Ma JZ; Dwivedi S; Havranek R; Fincke C; DeFronzo R; Bannayan GA; Schenker S; Cusi K
    N Engl J Med; 2006 Nov; 355(22):2297-307. PubMed ID: 17135584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regression of steatohepatitis-related cirrhosis.
    Deniz K; Özcan S; Özbakır Ö; Patıroğlu TE
    Semin Liver Dis; 2015 May; 35(2):199-202. PubMed ID: 25974904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review article: type 2 diabetes and chronic liver disease in the Verona diabetes study.
    Trombetta M; Spiazzi G; Zoppini G; Muggeo M
    Aliment Pharmacol Ther; 2005 Nov; 22 Suppl 2():24-7. PubMed ID: 16225467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ultrasonographic and biochemical evaluation of visceral obesity in obese women with non-alcoholic fatty liver disease.
    Fenkci S; Rota S; Sabir N; Akdag B
    Eur J Med Res; 2007 Feb; 12(2):68-73. PubMed ID: 17369120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of a 10-week weight loss camp on fatty liver disease and insulin sensitivity in obese Danish children.
    Grønbæk H; Lange A; Birkebæk NH; Holland-Fischer P; Solvig J; Hørlyck A; Kristensen K; Rittig S; Vilstrup H
    J Pediatr Gastroenterol Nutr; 2012 Feb; 54(2):223-8. PubMed ID: 21760546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of diet and nutritional management in non-alcoholic fatty liver disease.
    Fan JG; Cao HX
    J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():81-7. PubMed ID: 24251710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds.
    Struben VM; Hespenheide EE; Caldwell SH
    Am J Med; 2000 Jan; 108(1):9-13. PubMed ID: 11059435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diabetes mellitus, obesity, and hepatic steatosis.
    Youssef W; McCullough AJ
    Semin Gastrointest Dis; 2002 Jan; 13(1):17-30. PubMed ID: 11944630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel aminosterol reverses diabetes and fatty liver disease in obese mice.
    Takahashi N; Qi Y; Patel HR; Ahima RS
    J Hepatol; 2004 Sep; 41(3):391-8. PubMed ID: 15336441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease.
    Ong J; Younossi ZM; Reddy V; Price LL; Gramlich T; Mayes J; Boparai N
    Liver Transpl; 2001 Sep; 7(9):797-801. PubMed ID: 11552214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonalcoholic steatohepatitis with improved hepatic fibrosis after weight reduction.
    Fujikawa K; Ohata K; Honda T; Miyazoe S; Ichikawa T; Ishikawa H; Hamasaki K; Nakao K; Toriyama K; Eguchi K
    Intern Med; 2004 Apr; 43(4):289-94. PubMed ID: 15168770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of a low-carbohydrate, ketogenic diet on nonalcoholic fatty liver disease: a pilot study.
    Tendler D; Lin S; Yancy WS; Mavropoulos J; Sylvestre P; Rockey DC; Westman EC
    Dig Dis Sci; 2007 Feb; 52(2):589-93. PubMed ID: 17219068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes.
    Fracanzani AL; Valenti L; Bugianesi E; Andreoletti M; Colli A; Vanni E; Bertelli C; Fatta E; Bignamini D; Marchesini G; Fargion S
    Hepatology; 2008 Sep; 48(3):792-8. PubMed ID: 18752331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of chronic p,p'-dichlorodiphenyldichloroethylene (DDE) exposure on high fat diet-induced alterations in glucose and lipid metabolism in male C57BL/6H mice.
    Howell GE; Mulligan C; Meek E; Chambers JE
    Toxicology; 2015 Feb; 328():112-22. PubMed ID: 25541407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.